Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
McDonald, J TysonEnguita, Francisco J
Taylor, Deanne
Griffin, Robert J
Priebe, Waldemar
Emmett, Mark R
Sajadi, Mohammad M
Harris, Anthony D
Clement, Jean
Dybas, Joseph M
Aykin-Burns, Nukhet
Guarnieri, Joseph W
Singh, Larry N
Grabham, Peter
Baylin, Stephen B
Yousey, Aliza
Pearson, Andrea N
Corry, Peter M
Saravia-Butler, Amanda
Aunins, Thomas R
Sharma, Sadhana
Nagpal, Prashant
Meydan, Cem
Foox, Jonathan
Mozsary, Christopher
Cerqueira, Bianca
Zaksas, Viktorija
Singh, Urminder
Wurtele, Eve Syrkin
Costes, Sylvain V
Davanzo, Gustavo Gastão
Galeano, Diego
Paccanaro, Alberto
Meinig, Suzanne L
Hagan, Robert S
Bowman, Natalie M
Wolfgang, Matthew C
Altinok, Selin
Sapoval, Nicolae
Treangen, Todd J
Moraes-Vieira, Pedro M
Vanderburg, Charles
Wallace, Douglas C
Schisler, Jonathan C
Mason, Christopher E
Chatterjee, Anushree
Meller, Robert
Beheshti, Afshin
Date
2021-09-30Journal
Cell ReportsPublisher
Elsevier Inc.Type
Article
Metadata
Show full item recordAbstract
MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient transcriptomic data, we determined that a circulating miRNA, miR-2392, is directly involved with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients positive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential for developing a minimally invasive COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans.Rights/Terms
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.Identifier to cite or link to this item
http://hdl.handle.net/10713/16852ae974a485f413a2113503eed53cd6c53
10.1016/j.celrep.2021.109839